Balaraman Kalyanaraman Selected Research

Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)

1/2022	Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation.
10/2020	Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone.
5/2010	Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Balaraman Kalyanaraman Research Topics

Disease

52	Neoplasms (Cancer) 05/2024 - 11/2002
11	Mitochondrial Diseases (Mitochondrial Disease) 01/2024 - 05/2009
11	Breast Neoplasms (Breast Cancer) 01/2023 - 08/2007
11	Inflammation (Inflammations) 10/2021 - 09/2002
10	Parkinson Disease (Parkinson's Disease) 02/2024 - 12/2010
7	Hypoxia (Hypoxemia) 05/2024 - 02/2011
7	Lung Neoplasms (Lung Cancer) 11/2023 - 05/2010
6	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2015
6	Carcinogenesis 05/2022 - 05/2010
6	Cardiotoxicity 01/2020 - 11/2002
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2017 - 05/2013
5	Carcinoma (Carcinomatosis) 01/2016 - 01/2014
4	Cardiomyopathies (Cardiomyopathy) 01/2020 - 02/2008
3	Melanoma (Melanoma, Malignant) 05/2024 - 01/2020
3	Colonic Neoplasms (Colon Cancer) 05/2024 - 01/2018
3	COVID-19 10/2021 - 01/2020
3	Heart Failure 01/2020 - 02/2008
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 08/2014
2	Neuroinflammatory Diseases 02/2024 - 11/2017
2	Brain Neoplasms (Brain Tumor) 02/2023 - 05/2018
2	Triple Negative Breast Neoplasms 01/2023 - 05/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2017 - 01/2010
2	Disease Progression 10/2017 - 10/2012
2	Non-alcoholic Fatty Liver Disease 10/2017 - 07/2015
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2013 - 01/2010
2	Reperfusion Injury 01/2013 - 09/2012
2	Hypertension (High Blood Pressure) 01/2010 - 03/2002
1	Glioma (Gliomas) 01/2023

Drug/Important Bio-Agent (IBA)

21	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 01/2010
18	AntioxidantsIBA 01/2023 - 01/2010
10	triphenylphosphoniumIBA 05/2024 - 10/2009
10	Metformin (Glucophage)FDA LinkGeneric 05/2024 - 01/2016
9	Superoxides (Superoxide)IBA 11/2022 - 03/2002
8	Oxidants (Oxidizing Agents)IBA 02/2023 - 09/2012
7	Proteins (Proteins, Gene)FDA Link 07/2023 - 09/2002
7	mito-carboxy proxylIBA 01/2018 - 01/2012
6	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 11/2022 - 08/2015
6	Phosphotransferases (Kinase)IBA 01/2022 - 11/2010
6	Adenosine Triphosphate (ATP)IBA 01/2020 - 05/2010
5	Atovaquone (Mepron)FDA Link 05/2024 - 01/2022
5	honokiolIBA 02/2023 - 11/2014
5	CytokinesIBA 10/2021 - 01/2013
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 02/2008
5	acetovanillone (apocynin)IBA 11/2017 - 10/2012
4	Oxygen (Dioxygen)IBA 05/2024 - 08/2013
4	CationsIBA 07/2023 - 12/2010
4	mitoquinoneIBA 01/2023 - 11/2010
4	EnzymesIBA 01/2022 - 04/2006
4	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2017 - 02/2011
3	NitrogenIBA 02/2024 - 08/2013
3	magnololIBA 02/2023 - 01/2020
3	Fluorescent Dyes (Fluorescent Probes)IBA 02/2023 - 10/2014
3	UbiquinoneIBA 01/2023 - 11/2010
3	Neuroprotective AgentsIBA 01/2022 - 12/2010
3	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA 01/2022 - 05/2010
3	Antineoplastic Agents (Antineoplastics)IBA 06/2021 - 04/2006
3	Free RadicalsIBA 10/2020 - 08/2014
3	nitroxylIBA 01/2018 - 10/2011
3	Hypoglycemic Agents (Hypoglycemics)IBA 12/2017 - 01/2016
3	diapocyninIBA 11/2014 - 10/2012
2	Acetylcysteine (Siran)FDA LinkGeneric 01/2023 - 11/2022
2	IronIBA 11/2022 - 05/2019
2	RNA (Ribonucleic Acid)IBA 05/2022 - 01/2019
2	lonidamineIBA 05/2022 - 01/2019
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 05/2022 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 04/2013
2	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2022 - 06/2021
2	PeroxiredoxinsIBA 01/2020 - 01/2019
2	CarbonIBA 11/2019 - 01/2017
2	Dexrazoxane (Zinecard)FDA LinkGeneric 05/2019 - 01/2013
2	Protein Isoforms (Isoforms)IBA 01/2019 - 01/2019
2	proxyl nitroxideIBA 01/2018 - 01/2017
2	Tyrosine (L-Tyrosine)FDA Link 10/2017 - 09/2002
2	Peroxynitrous Acid (Peroxynitrite)IBA 10/2017 - 07/2015
2	Leucine (L-Leucine)FDA Link 11/2014 - 08/2013
2	Reactive Nitrogen SpeciesIBA 10/2014 - 09/2002
2	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 01/2013 - 05/2009
2	3-nitrotyrosineIBA 09/2012 - 07/2011
2	Cisplatin (Platino)FDA LinkGeneric 07/2012 - 01/2012
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2011 - 08/2007
2	CholesterolIBA 10/2011 - 08/2007
2	Caspase 3 (Caspase-3)IBA 02/2008 - 04/2006
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2007 - 04/2006
2	ArginaseIBA 08/2007 - 05/2007
1	Tamoxifen FDA LinkGeneric 05/2024
1	IACS-010759IBA 05/2024
1	Green Fluorescent ProteinsIBA 05/2024
1	ElementsIBA 05/2024
1	alpha-SynucleinIBA 02/2024
1	Volatile Fatty AcidsIBA 02/2024
1	PhytochemicalsIBA 02/2023
1	PolyphenolsIBA 02/2023
1	ProdrugsIBA 02/2023
1	coenzyme Q10 (CoQ10)IBA 01/2023
1	Mesylates (Mesylate)IBA 01/2023

Therapy/Procedure

15	Therapeutics 02/2023 - 11/2002
6	Immunotherapy 05/2024 - 03/2014
3	Chemoprevention 05/2022 - 04/2015
2	Radiotherapy 05/2024 - 06/2021
2	Drug Therapy (Chemotherapy) 01/2020 - 05/2019